Proposals for the classification of the myelodysplastic syndromes - PubMed (original) (raw)
- PMID: 6952920
Proposals for the classification of the myelodysplastic syndromes
J M Bennett et al. Br J Haematol. 1982 Jun.
Abstract
New diagnostic criteria for the diagnosis of the various myelodysplastic syndromes (MDS) are proposed, and a detailed description is given of the features that may help define MDS. Five MDS are described: (1) refractory anaemia (RA), (2) RA with ring sideroblasts, (3) RA with excess of blasts (RAEB), (4) chronic myelomonocytic leukaemia (CMML), and (5) RAEB 'in transformation'. One of the main distinguishing features of these conditions is the proportion of blast cells in the peripheral blood (PB) and/or bone marrow (BM). The morphological features of the blast cells that are of diagnostic importance have been redefined. In RA, with or without ringed sideroblasts, there are fewer than 1% of blasts in the PB and fewer than 5% in the BM; RAEB is defined as having between 5% and 20% of blasts in the BM and fewer than 5% in the PB; RAEB in transformation (a newly defined category) will be considered when any of the following features is present: (i) more than 5% of blasts in the PB, (ii) 20-30% in the BM, and (iii) the presence of Auer rods in granulocyte precursors in BM or PB. In accordance with these newly defined criteria, it is now proposed that over 30% of bone marrow blasts will suffice for the diagnosis of acute myeloid leukaemia (AML) in any of its forms (M1-M6). The proposed descriptions of the MDS should facilitate the interpretation of data emerging from cytogenetic and bone marrow culture studies and the search for features of possible prognostic significance. Recognition of the new category, RAEB in transformation, may throw light on the pathogenesis of AML.
Similar articles
- Myelodysplastic syndromes: a study of 101 cases according to the FAB classification.
Vallespi T, Torrabadella M, Julia A, Irriguible D, Jaen A, Acebedo G, Triginer J. Vallespi T, et al. Br J Haematol. 1985 Sep;61(1):83-92. doi: 10.1111/j.1365-2141.1985.tb04063.x. Br J Haematol. 1985. PMID: 3863667 - Refractory anaemia with excess of blasts in transformation re-evaluated with the WHO criteria: identification of subgroups with different survival.
Breccia M, Latagliata R, Carmosino I, Gentilini F, D'Elia GM, Levi A, Natalino F, Frustaci A, De Cuia MR, Alimena G. Breccia M, et al. Acta Haematol. 2007;117(4):221-5. doi: 10.1159/000098957. Epub 2007 Jan 26. Acta Haematol. 2007. PMID: 17259693 - Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A, Jäger E, Sagaster V, Streubel B, Wimazal F, Sperr WR, Welterman A, Schwarzinger I, Frommlet F, Haas OA, Valent P, Lechner K, Geissler K, Ohler L. Berer A, et al. Ann Hematol. 2003 May;82(5):271-7. doi: 10.1007/s00277-003-0619-z. Epub 2003 Mar 22. Ann Hematol. 2003. PMID: 12739063 - The myelodysplastic syndromes.
Masey JA. Masey JA. Br J Biomed Sci. 1997 Mar;54(1):65-70. Br J Biomed Sci. 1997. PMID: 9167309 Review. - [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert M. Schmitt-Graeff A, et al. Pathologe. 2000 Jan;21(1):1-15. doi: 10.1007/s002920050001. Pathologe. 2000. PMID: 10663664 Review. German.
Cited by
- Hematopoietic Stem Cell Transplantation in the Management of Myelodysplastic Syndrome: A Retrospective, Current, and Future Perspective.
Qimudesiren, Yin W, Wang Y, Qing G, Bao J, Chaomurilige, Chen S, Qian L. Qimudesiren, et al. Cell Transplant. 2024 Jan-Dec;33:9636897241284283. doi: 10.1177/09636897241284283. Cell Transplant. 2024. PMID: 39374074 Free PMC article. Review. - How we diagnose Myelodysplastic syndromes.
Oster HS, Mittelman M. Oster HS, et al. Front Oncol. 2024 Sep 13;14:1415101. doi: 10.3389/fonc.2024.1415101. eCollection 2024. Front Oncol. 2024. PMID: 39346739 Free PMC article. Review. - Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real-world cohort of patients with lower-risk MDS.
Mazzeo P, Ganster C, Wiedenhöft J, Shirneshan K, Rittscher K, Brzuszkiewicz EB, Steinemann D, Schieck M, Müller-Thomas C, Treiber H, Braulke F, Germing U, Sockel K, Balaian E, Schanz J, Platzbecker U, Götze KS, Haase D. Mazzeo P, et al. Hemasphere. 2024 Sep 23;8(9):e70014. doi: 10.1002/hem3.70014. eCollection 2024 Sep. Hemasphere. 2024. PMID: 39315323 Free PMC article. - Distinct mutation features and its clinical significance in myelodysplastic syndromes with normal karyotype.
Huang N, Chang C, Wu L, He Q, Zhang Z, Li X, Xu F. Huang N, et al. Ann Hematol. 2024 Nov;103(11):4485-4495. doi: 10.1007/s00277-024-06005-2. Epub 2024 Sep 20. Ann Hematol. 2024. PMID: 39302466 - MDS patient registries - achievements and challenges.
Steinmetz T, Totzke U, Kasprzak A, Schmitz S, Gattermann N, Germing U. Steinmetz T, et al. Ann Hematol. 2024 Aug 23. doi: 10.1007/s00277-024-05925-3. Online ahead of print. Ann Hematol. 2024. PMID: 39174754 Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous